Download PDF

1. Company Snapshot

1.a. Company Description

Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape.The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas.It operates in the United States, Europe, and South America.


The company was founded in 2008 and is based in Luxembourg.

Show Full description

1.b. Last Insights on MLEC

Moolec Science's recent performance was negatively impacted by the company's decision to effect a 1-for-10 reverse stock split on May 14, 2025, which resulted in a significant reduction in the number of outstanding shares. This move was likely aimed at regaining NASDAQ compliance, as the company announced on June 11, 2025, that it had regained compliance with Listing Rule 5550(a)(2) after the reverse stock split.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

3. NewsRoom

Card image cap

Moolec Science (MLEC) Stock Explodes 90% After GLA Update

Feb -13

Card image cap

Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 Crushing

Feb -13

Card image cap

Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions

Jan -30

Card image cap

Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

Jan -23

Card image cap

Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

Jan -22

Card image cap

Moolec Science Announces Effectiveness of Share Consolidation

Jan -06

Card image cap

Moolec Receives Staff Determination Letter and Provides Update on Nasdaq Listing Compliance Status

Dec -31

Card image cap

Moolec Science SA Announces the Implementation of a Share Consolidation of Its Ordinary Shares, Par Value U.S.$0.10 Per Share (the "Shares")

Dec -31

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Science-based Food Ingredients

Expected Growth: 9.27%

Moolec Science SA's 9.27% growth in Science-based Food Ingredients is driven by increasing demand for sustainable and healthy food options, advancements in biotechnology, and rising consumer awareness of environmental impact. Additionally, growing investments in R&D, strategic partnerships, and expanding distribution channels contribute to the company's rapid growth.

7. Detailed Products

Microbial-based protein production

Moolec Science SA uses microbial fermentation to produce high-quality protein ingredients for the food, feed, and pharmaceutical industries.

Cell-free protein expression

Moolec Science SA offers cell-free protein expression technology for the production of recombinant proteins, including enzymes, antibodies, and vaccines.

Microbial-based enzyme production

Moolec Science SA develops and produces microbial-based enzymes for various industries, including food, feed, and pharmaceuticals.

Biomanufacturing services

Moolec Science SA provides contract biomanufacturing services for the production of microbial-based products, including proteins, enzymes, and small molecules.

Research and development services

Moolec Science SA offers research and development services for the development of new microbial-based products and processes.

8. Moolec Science SA's Porter Forces

Forces Ranking

Threat Of Substitutes

Moolec Science SA has a moderate threat of substitutes due to the presence of alternative products in the market, but the company's unique technology and high-quality products reduce the likelihood of customers switching to substitutes.

Bargaining Power Of Customers

Moolec Science SA has a low bargaining power of customers due to the company's strong brand reputation and high-quality products, which reduces the customers' ability to negotiate prices.

Bargaining Power Of Suppliers

Moolec Science SA has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market, but the company's long-term contracts and strong relationships with suppliers reduce the suppliers' bargaining power.

Threat Of New Entrants

Moolec Science SA has a high threat of new entrants due to the growing demand for biotechnology products and the relatively low barriers to entry in the industry, which increases the likelihood of new competitors entering the market.

Intensity Of Rivalry

Moolec Science SA operates in a highly competitive industry with several established players, which increases the intensity of rivalry and requires the company to continuously innovate and improve its products to maintain its market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 20.75%
Debt Cost 3.95%
Equity Weight 79.25%
Equity Cost 1.49%
WACC 2.00%
Leverage 26.18%

11. Quality Control: Moolec Science SA passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Sol-Gel Technologies

A-Score: 4.0/10

Value: 4.6

Growth: 3.6

Quality: 5.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Stock-Card
Oxford Biomedica

A-Score: 3.6/10

Value: 6.4

Growth: 2.0

Quality: 3.1

Yield: 0.0

Momentum: 8.5

Volatility: 1.3

1-Year Total Return ->

Stock-Card
Moolec Science

A-Score: 3.1/10

Value: 7.8

Growth: 3.3

Quality: 2.5

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

Stock-Card
InflaRx

A-Score: 2.9/10

Value: 7.4

Growth: 5.9

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

Stock-Card
Exscientia

A-Score: 2.8/10

Value: 7.0

Growth: 2.1

Quality: 3.4

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

Stock-Card
Affimed

A-Score: 2.3/10

Value: 8.0

Growth: 0.9

Quality: 4.3

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

8.83$

Current Price

8.83$

Potential

-0.01%

Expected Cash-Flows